Details

Contributors. <p>Preface.</p> <p><b>Second I: Introduction.</b></p> <p>1. At the Precarious Cusp of Oncogenomics (Charles Brenner).</p> <p><b>Second II: Molecular Profiling in Cancer: DNA, RNA and Protein.</b></p> <p>2. Genome-Wide Searches for Mutations in Human Cancer (Michael R. Stratton, P. Andrew Futreal, and Richard Wooster).</p> <p>3. Molecular Cytogenetics: Increasing Resolution Using Array-Based CGH (Anne Kallioniemi).</p> <p>4. SNPs and Functional Polymorphisms in Cancer (Penelope E. Bonnen and David L. Nelson).</p> <p>5. Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility (Therese Sørlie, Anne-Lise Børresen-Dale, Per E. Lønning, Patrick O. Brown, and David Botstein).</p> <p>6. Classifying Hereditary Cancers and Phenocopies of Hereditary Cancers Using Expression Arrays (Mary B. Daly, Alicia Parlanti, and David Duggan).</p> <p>7. Linking Drugs and Genes: Pharmacogenomics, Pharmacoproteomics, Bioinformatics, and the NCI-60 (John N. Weinstein).</p> <p>8. Tissue Microanalysis: Profiling Cancer Stages (Michael A. Tangrea and Michael R. Emmert-Buck).</p> <p>9. Proteomic s in Bladder Cancer (Julio E. Celis, Irina Gromova, Fritz Rank and Pavel Gromov).</p> <p><b>Second III: Model Systems.</b></p> <p>10. Chemical and Genetic Methods to Validate Targets in Nonmammalian Organisms (Tia M. Maiolatesi and Charles Brenner).</p> <p>11. Mouse Models of Cancer (Debrah M. Thompson, Louise van der Weyden, Patrick J. Biggs, Yeun-Jun Chung and Allan Bradley).</p> <p>12. Genome-Wide Modifier Screens: How the Genetics of Cancer Penetrance May Shape the Future of Prevention and Treatment (Linda D. Siracusa, Karen A. Silverman, Revati Koratkar, Marina Markova and Arthur M. Buchberg).</p> <p><b>Second IV: Molecularly Targeted Drugs.</b></p> <p>13. Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches (Paul Nghiem, Yong-son Kim and Stuart L. Schreiber).</p> <p>14. Ras Superfamily-Directed Compounds (George C. Prendergast).</p> <p>15. Clinomics: Post-Genomic Cancer Care (Daniel D. Von Hoff, Haiyong Han, and David Bearss).</p> <p><b>Part V: Conclusion).</b></p> <p>16. Oncogenomics and the NCI Director’s Vision for 2015 (Andrew C. von Eschenbach).</p> <p>Index.</p>

"…has many useful components for both basic scientists and clinicians involved in the application of genomics to an understanding of cancer diagnosis and therapy." (<i>The Quarterly Review of Biology</i>, March 2006) <p>"…this book will be an appreciated resource for cancer researchers along with sophisticated oncologists and other health care providers." (<i>American Journal of Medical Genetics</i>, June 1, 2005)</p> <p>"...the first of its kind devoted to the genomics of cancer...very good reading...the essence of the book is to bring together scientists from various specialties and share the same language…” (<i>New England Journal of Medicine</i>, October 28, 2004)</p> <p>"...an excellent source of basic, up-to-date, readable material...in-depth explanations...already looking forward to the next edition..." (<i>British Journal of Cancer Management</i>, Vol 1(1), Summer 2004)</p>

<p><strong>Charles Brenner</strong> is Director of the Cancer Mechanisms Program at Dartmouth's Norris Cotton Cancer Center in New Hampshire. He trained in yeast molecular biology with Anthony Brake at Chiron and yeast genetics with Kunihiro Matsumoto at DNAX before earning his Ph.D. in the biochemistry department at Stanford with Robert Fuller. In 1993, as a Leukemia Society Fellow, Brenner moved to Brandeis to train in X-ray crystallography with Gregory Petsko and Dagmar Ringe and then took an independent position at the Kimmel Cancer Center at Jefferson in 1996. Brenner rose to head the KCC's Program in Structural Biology and Bioinformatics in 2000 and joined Dartmouth Medical School's faculties of Genetics and Biochemistry in 2003. Dr. Brenner's research group uses genetics, enzymology and X-ray crystallography to dissect the cellular pathways perturbed by loss of the <i>FHIT</i> tumor suppressor gene, which is lost early in the development of many tumors of epithelial origin. <p><strong>David Duggan</strong> received his Ph.D. in 1997 in Human Genetics at Pittsburgh and trained with Jeffrey Trent in microarray analysis of breast and prostate cancer from 1998 to 2000 at the National Human Genome Research Institute. Duggan then served as an associate investigator at the National Institute of Arthritis and Musculoskeletal and Skin Diseases until 2003 when he took his current position at the Translational Genomics Research Institute in Arizona. Dr. Duggan's laboratory uses SNP genotyping and microarray analysis to investigate the genetic basis of human diseases.

Diagnoses termed "cancer" consist of hundreds of different diseases with as many constellations of genetic alterations. Genomic technologies have made it possible to identify all of the tumor-specific mutations, to profile individual tumors at the DNA, RNA, and protein levels, and to test in cellular and animal systems the responses of particular genotypes to particular drugs. Oncogenomics and allied disciplines have identified new targets for genotype-specific treatments and provided strategies to validate these targets and to develop drugs. With the potential need to stratify patients by genotype, clinical testing of targeted drugs has become more complicated while expectations of patients, investors, and funding agencies have become accelerated. Oncogenomics: Molecular Approaches to Cancer offers the first rigorous yet broadly accessible treatment of the impact of genomics on cancer research and care. Clearly written by world-renowned scientists in the field, and edited for overall cohesion, Oncogenomics progresses logically from molecular profiling to model systems, cancer pharmacology, and clinical trials. Oncogenomics <ul> <li>Covers cutting-edge issues such as array-based diagnostics, pharmaco-genomics, and molecularly targeted therapeutics</li> <li>Includes discussions of ethical, legal, and social issues related to cancer genomics and clinical trials</li> <li>Provides links to online oncogenomic resources and references</li> </ul> <p>Recognizing the multidisciplinary character of Oncogenomics, the editors include an advanced introduction to cancer genetics and cancer pharmacology that makes accessible state-of-the-art topics such as expression profiling, SNPs in cancer, tissue microarrays, and chemical and genetic validation studies. Scientists, oncologists, and other healthcare professionals, as well as advanced students, will find Oncogenomics an essential resource for elucidating this exciting field.</p>

US